Literature DB >> 30508414

Evidence of an anti-inflammatory toll-like receptor 9 (TLR 9) pathway in adipocytes.

Miriam Thomalla1, Andreas Schmid1, Elena Neumann2, Petra Ina Pfefferle3, Ulf Müller-Ladner2, Andreas Schäffler1, Thomas Karrasch1.   

Abstract

Adipocytes express various pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) and actively participate in anti-bacterial and anti-viral host defence. Obesity is associated with adipose tissue PRR expression. The potential role of Toll-like receptor 9 (TLR9) in adipocytes has not yet been investigated. Here, we evaluated TLR9 expression during adipocyte differentiation (AD) of 3T3-L1 adipocytes, in primary murine adipocytes and in different murine and human adipose tissue depots by real-time PCR, immunocytochemistry and immunohistochemistry. TLR9 expression was inhibited using specific siRNA-mediated knockdown, and TLR9 signaling was induced using specific class A, B and C agonistic CpG-oligodeoxynucleotide (ODN) treatment vs ODN controls in 3T3-L1 adipocytes and in primary murine adipocytes from Tlr9wt/wt vs Tlr9-/- mice. We found that TLR9 gene expression is induced during AD and that TLR9 protein is expressed in murine gonadal and human visceral adipocytes. AD depends on intact TLR9 expression. Tlr9-/- mice demonstrate significantly reduced adiponectin serum levels, while siRNA-mediated TLR9 knockdown led to reduced adiponectin mRNA expression in adipocytes. TLR9 ligands (CpG-ODNs) inhibit pro-inflammatory resistin secretion in mature 3T3-L1 adipocytes. Tlr9-/- as compared to Tlr9wt/wt adipocytes exhibit increased resistin and MCP1 secretion and reduced adiponectin secretion into cell culture supernatants, while TLR9 ligands (ODNs) show differential effects in Tlr9-/- vs Tlr9wt/wt primary murine adipocytes. TLR9 expression is significantly increased in visceral compared to subcutaneous adipose tissue depots in non-diabetic obese patients and correlates with systemic resistin levels in a compartment-specific manner. Thus, adipocytic TLR9 is a putative, new protective factor during (obesity-associated) adipose tissue inflammation.

Entities:  

Keywords:  CpG; TLR9; adipocyte; adipokine; adipose tissue; inflammation; pattern recognition receptor

Mesh:

Substances:

Year:  2019        PMID: 30508414     DOI: 10.1530/JOE-18-0326

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  9 in total

Review 1.  Adipose tissue inflammation and metabolic dysfunction in obesity.

Authors:  Tatsuo Kawai; Michael V Autieri; Rosario Scalia
Journal:  Am J Physiol Cell Physiol       Date:  2020-12-23       Impact factor: 4.249

Review 2.  TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism.

Authors:  Christopher R Shepard
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-29       Impact factor: 5.555

3.  TIR-Domain-Containing Adaptor-Inducing Interferon-β (TRIF) Is Involved in Glucose Metabolism in Adipose Tissue through the Insulin/AKT Signaling Pathway.

Authors:  Junling Yang; Ken-Ichiro Fukuchi
Journal:  Int J Endocrinol       Date:  2020-12-09       Impact factor: 3.257

Review 4.  Toll-like receptor-mediated innate immunity against herpesviridae infection: a current perspective on viral infection signaling pathways.

Authors:  Wenjin Zheng; Qing Xu; Yiyuan Zhang; Xiaofei E; Wei Gao; Mogen Zhang; Weijie Zhai; Ronaldjit Singh Rajkumar; Zhijun Liu
Journal:  Virol J       Date:  2020-12-09       Impact factor: 4.099

Review 5.  Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework.

Authors:  Laure-Alix Clerbaux; Maria Cristina Albertini; Núria Amigó; Anna Beronius; Gillina F G Bezemer; Sandra Coecke; Evangelos P Daskalopoulos; Giusy Del Giudice; Dario Greco; Lucia Grenga; Alberto Mantovani; Amalia Muñoz; Elma Omeragic; Nikolaos Parissis; Mauro Petrillo; Laura A Saarimäki; Helena Soares; Kristie Sullivan; Brigitte Landesmann
Journal:  J Clin Med       Date:  2022-07-31       Impact factor: 4.964

6.  Toll-like Receptor 7 (TLR7) Is Expressed in Adipocytes and the Pharmacological TLR7 Agonist Imiquimod and Adipocyte-Derived Cell-Free Nucleic Acids (cfDNA) Regulate Adipocyte Function.

Authors:  Miriam Thomalla; Andreas Schmid; Julia Hehner; Sebastian Koehler; Elena Neumann; Ulf Müller-Ladner; Andreas Schäffler; Thomas Karrasch
Journal:  Int J Mol Sci       Date:  2022-07-30       Impact factor: 6.208

7.  Antitumor Immunity from Abdominal Flap-Embedded Therapeutic Cancer Vaccine.

Authors:  Xiaoling Liu; Junhua Mai; Chaoyang Meng; Aldona J Spiegel; Wei Wei; Haifa Shen
Journal:  Int J Nanomedicine       Date:  2022-01-11

Review 8.  Nutritional Impact and Its Potential Consequences on COVID-19 Severity.

Authors:  Esmaeil Mortaz; Gillina Bezemer; Shamila D Alipoor; Mohammad Varahram; Sharon Mumby; Gert Folkerts; Johan Garssen; Ian M Adcock
Journal:  Front Nutr       Date:  2021-07-05

9.  CTRP-3 Regulates NOD1-mediated Inflammation and NOD1 Expression in Adipocytes and Adipose Tissue.

Authors:  Andreas Schmid; Andreas Schäffler; Thomas Karrasch
Journal:  Inflammation       Date:  2021-06-24       Impact factor: 4.092

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.